Viking Therapeutics Inc is a US-based pharmaceutical company with a Risk Rating Score of 26.5, placing it in the Medium Risk category. Specializing in biopharmaceutical development for metabolic and endocrine disorders, their ESG-focused clinical program includes products like VK2809, VK5211, and VK0214. VK2809 and VK0214 are unique orally available products targeting the thyroid hormone receptor beta, while VK5211 is a non-steroidal selective androgen receptor modulator.